A virus-like particle-based anti-nerve growth factor vaccine reduces inflammatory hyperalgesia: Potential long-term therapy for chronic pain

Journal of Immunology

Volumn 186, Issue 3, 2011, Pages 1769-1780

  Röhn, Till A ^a,d   Ralvenius, William T ^b,c   Paul, Jolly ^b   Borter, Petra ^a   Hernandez, Marcela ^a   Witschi, Robert ^b,c   Grest, Paula ^b   Zeilhofer, Hanns Ulrich ^b,c   Bachmann, Martin F ^a   Jennings, Gary T ^a  

^a CYTOS BIOTECHNOLOGY AG   (Switzerland)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c ETH ZURICH   (Switzerland)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; NERVE GROWTH FACTOR RECEPTOR; ZYMOSAN;

ACTIVE IMMUNIZATION; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTHRITIS; ARTICLE; BACTERIOPHAGE; BACTERIOPHAGE QBETA; CELL STRAIN HEK293; CHRONIC PAIN; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRUS LIKE AGENT;

ACUTE DISEASE; ALLOLEVIVIRUS; ANIMALS; ANTIBODIES, VIRAL; CELL LINE, TUMOR; CHRONIC DISEASE; DRUG EVALUATION, PRECLINICAL; HYPERALGESIA; INFLAMMATION; INFLAMMATION MEDIATORS; MALE; MICE; MICE, INBRED C57BL; MICE, INBRED DBA; NERVE GROWTH FACTORS; NEUTRALIZATION TESTS; PAIN; RATS; TIME FACTORS; VACCINES, CONJUGATE; VACCINES, VIRUS-LIKE PARTICLE;

EID: 79251545500     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1000030     Document Type: Article

References (58)

1. Pezet, S., and S. B. McMahon. 2006. Neurotrophins: mediators and modulators of pain. Annu. Rev. Neurosci. 29: 507-538.
2. Watson, J. J., S. J. Allen, and D. Dawbarn. 2008. Targeting nerve growth factor in pain: what is the therapeutic potential? BioDrugs 22: 349-359.
3. J. Fricker. 2008. Pain in Europe: a report. Available at: http://www.mundipharma.at/ressourcen/D-2-%20Survey%20of%20Pain%20In%20Europe%20- %20Report%20for%20Europe.pdf. Accessed: December 2010.
4. Breivik, H., B. Collett, V. Ventafridda, R. Cohen, and D. Gallacher. 2006. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur. J. Pain 10: 287-333.
5. Hefti, F. F., A. Rosenthal, P. A. Walicke, S. Wyatt, G. Vergara, D. L. Shelton, and A. M. Davies. 2006. Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol. Sci. 27: 85-91.
6. Campbell, J. N., and R. A. Meyer. 2006. Mechanisms of neuropathic pain. Neuron 52: 77-92.
7. Huang, J., X. Zhang, and P. A. McNaughton. 2006. Inflammatory pain: the cellular basis of heat hyperalgesia. Curr. Neuropharmacol. 4: 197-206.
8. Patel, T. D., A. Jackman, F. L. Rice, J. Kucera, and W. D. Snider. 2000. Development of sensory neurons in the absence of NGF/TrkA signaling in vivo. Neuron 25: 345-357.
9. Petruska, J. C., and L. M. Mendell. 2004. The many functions of nerve growth factor: multiple actions on nociceptors. Neurosci. Lett. 361: 168-171.
10. McMahon, S. B. 1996. NGF as a mediator of inflammatory pain. Philos. Trans. R. Soc. Lond. B Biol. Sci. 351: 431-440.
11. Lewin, G. R., and L. M. Mendell. 1993. Nerve growth factor and nociception. Trends Neurosci. 16: 353-359.
12. Lewin, G. R., A. M. Ritter, and L. M. Mendell. 1993. Nerve growth factor-induced hyperalgesia in the neonatal and adult rat. J. Neurosci. 13: 2136-2148.
13. Bergmann, I., R. Reiter, K. V. Toyka, and M. Koltzenburg. 1998. Nerve growth factor evokes hyperalgesia in mice lacking the low-affinity neurotrophin receptor p75. Neurosci. Lett. 255: 87-90.
14. McMahon, S. B., M. P. Armanini, L. H. Ling, and H. S. Phillips. 1994. Expression and coexpression of Trk receptors in subpopulations of adult primary sensory neurons projecting to identified peripheral targets. Neuron 12: 1161-1171.
15. Chuang, H. H., E. D. Prescott, H. Kong, S. Shields, S. E. Jordt, A. I. Basbaum, M. V. Chao, and D. Julius. 2001. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5)P2-mediated inhibition. Nature 411: 957-962.
16. Kawamoto, K., J. Aoki, A. Tanaka, A. Itakura, H. Hosono, H. Arai, Y. Kiso, and H. Matsuda. 2002. Nerve growth factor activates mast cells through the collaborative interaction with lysophosphatidylserine expressed on the membrane surface of activated platelets. J. Immunol. 168: 6412-6419.
17. Lewin, G. R., A. Rueff, and L. M. Mendell. 1994. Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci. 6: 1903-1912.
18. Dyck, P. J., S. Peroutka, C. Rask, E. Burton, M. K. Baker, K. A. Lehman, D. A. Gillen, J. L. Hokanson, and P. C. O'Brien. 1997. Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology 48: 501-505.
19. Aloe, L., M. A. Tuveri, U. Carcassi, and R. Levi-Montalcini. 1992. Nerve growth factor in the synovial fluid of patients with chronic arthritis. Arthritis Rheum. 35: 351-355.
20. Halliday, D. A., C. Zettler, R. A. Rush, R. Scicchitano, and J. D. McNeil. 1998. Elevated nerve growth factor levels in the synovial fluid of patients with inflammatory joint disease. Neurochem. Res. 23: 919-922.
21. Lowe, E. M., P. Anand, G. Terenghi, R. E. Williams-Chestnut, D. V. Sinicropi, and J. L. Osborne. 1997. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br. J. Urol. 79: 572-577.
22. Miller, L. J., K. A. Fischer, S. J. Goralnick, M. Litt, J. A. Burleson, P. Albertsen, and D. L. Kreutzer. 2002. Nerve growth factor and chronic prostatitis/chronic pelvic pain syndrome. Urology 59: 603-608.
23. Oddiah, D., P. Anand, S. B. McMahon, and M. Rattray. 1998. Rapid increase of NGF, BDNF and NT-3 mRNAs in inflamed bladder. Neuroreport 9: 1455-1458. (Pubitemid 28264269)
24. Sarchielli, P., and V. Gallai. 2004. Nerve growth factor and chronic daily headache: a potential implication for therapy. Expert Rev. Neurother. 4: 115-127.
25. Woolf, C. J., A. Allchorne, B. Safieh-Garabedian, and S. Poole. 1997. Cytokines, nerve growth factor and inflammatory hyperalgesia: the contribution of tumour necrosis factor alpha. Br. J. Pharmacol. 121: 417-424.
26. Shelton, D. L., J. Zeller, W. H. Ho, J. Pons, and A. Rosenthal. 2005. Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain 116: 8-16.
27. Sevcik, M. A., J. R. Ghilardi, C. M. Peters, T. H. Lindsay, K. G. Halvorson, B. M. Jonas, K. Kubota, M. A. Kuskowski, L. Boustany, D. L. Shelton, and P. W. Mantyh. 2005. Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain 115: 128-141.
28. Lane, N. E., T. J. Schnitzer, C. A. Birbara, M. Mokhtarani, D. L. Shelton, M. D. Smith, and M. T. Brown. 2010. Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med. 363: 1521-1531.
29. 2009. In: ClinicalTrials.gov. National Library of Medicine, Bethesda, MD. Available at: http://www.clinicaltrials.gov/ct2/results?term=Tanezumab. Accessed: December 23, 2010.
30. Ambühl, P. M., A. C. Tissot, A. Fulurija, P. Maurer, J. Nussberger, R. Sabat, V. Nief, C. Schellekens, K. Sladko, K. Roubicek, et al. 2007. A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity. J. Hypertens. 25: 63-72.
31. Fulurija, A., T. A. Lutz, K. Sladko, M. Osto, P. Y. Wielinga, M. F. Bachmann, and P. Saudan. 2008. Vaccination against GIP for the treatment of obesity. PLoS ONE 3: e3163.
32. Röhn, T. A., G. T. Jennings, M. Hernandez, P. Grest, M. Beck, Y. Zou, M. Kopf, and M. F. Bachmann. 2006. Vaccination against IL-17 suppresses autoimmune arthritis and encephalomyelitis. Eur. J. Immunol. 36: 2857-2867.
33. Spohn, G., and M. F. Bachmann. 2007. Targeting osteoporosis and rheumatoid arthritis by active vaccination against RANKL. Adv. Exp. Med. Biol. 602: 135-142.
34. Spohn, G., R. Guler, P. Johansen, I. Keller, M. Jacobs, M. Beck, F. Rohner, M. Bauer, K. Dietmeier, T. M. Kündig, et al. 2007. A virus-like particle-based vaccine selectively targeting soluble TNF-alpha protects from arthritis without inducing reactivation of latent tuberculosis. J. Immunol. 178: 7450-7457.
35. Spohn, G., I. Keller, M. Beck, P. Grest, G. T. Jennings, and M. F. Bachmann. 2008. Active immunization with IL-1 displayed on virus-like particles protects from autoimmune arthritis. Eur. J. Immunol. 38: 877-887.
36. Henken, D. B., and J. R. Martin. 1993. Neural antigen detection in mouse tissues is not impaired by decalcification. Acta Neuropathol. 86: 176-178.
37. Sidler, C., F. Parpan, and J.-M. Fritschy. 2010. Main protocol for immunohistochemistry and histology. Available at: http://www.pharma.uzh.ch/ research/neuromorphology/researchareas/neuromorphology/Protocols/ protocol-immuno.pdf. Accessed: November 6, 2010.
38. Chen, X., J. W. Gawryluk, J. F. Wagener, O. Ghribi, and J. D. Geiger. 2008. Caffeine blocks disruption of blood brain barrier in a rabbit model of Alzheimer's disease. J. Neuroinflammation 5: 12.
39. van Vliet, E. A., S. da Costa Araújo, S. Redeker, R. van Schaik, E. Aronica, and J. A. Gorter. 2007. Blood-brain barrier leakage may lead to progression of temporal lobe epilepsy. Brain 130: 521-534.
40. Gritti, I., P. Henny, F. Galloni, L. Mainville, M. Mariotti, and B. E. Jones. 2006. Stereological estimates of the basal forebrain cell population in the rat, including neurons containing choline acetyltransferase, glutamic acid decarboxylase or phosphate-activated glutaminase and colocalizing vesicular glutamate transporters. Neuroscience 143: 1051-1064.
41. Seidah, N. G., S. Benjannet, S. Pareek, D. Savaria, J. Hamelin, B. Goulet, J. Laliberte, C. Lazure, M. Chrétien, and R. A. Murphy. 1996. Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. Biochem. J. 314: 951-960.
42. Roubenoff, R., L. M. Freeman, D. E. Smith, L. W. Abad, C. A. Dinarello, and J. J. Kehayias. 1997. Adjuvant arthritis as a model of inflammatory cachexia. Arthritis Rheum. 40: 534-539.
43. Capsoni, S., C. Tiveron, G. Amato, D. Vignone, and A. Cattaneo. 2010. Peripheral neutralization of nerve growth factor induces immunosympathectomy and central neurodegeneration in transgenic mice. J. Alzheimers Dis. 20: 527-546.
44. Ruberti, F., S. Capsoni, A. Comparini, E. Di Daniel, J. Franzot, S. Gonfloni, G. Rossi, N. Berardi, and A. Cattaneo. 2000. Phenotypic knockout of nerve growth factor in adult transgenic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci. 20: 2589-2601.
45. Lynch, N. J., C. L. Willis, C. C. Nolan, S. Roscher, M. J. Fowler, E. Weihe, D. E. Ray, and W. J. Schwaeble. 2004. Microglial activation and increased synthesis of complement component C1q precedes blood-brain barrier dysfunction in rats. Mol. Immunol. 40: 709-716.
46. Bachmann, M. F., U. H. Rohrer, T. M. Kündig, K. Bürki, H. Hengartner, and R. M. Zinkernagel. 1993. The influence of antigen organization on B cell responsiveness. Science 262: 1448-1451.
47. Maurer, P., and M. F. Bachmann. 2007. Vaccination against nicotine: an emerging therapy for tobacco dependence. Expert Opin. Investig. Drugs 16: 1775-1783.
48. Tissot, A. C., P. Maurer, J. Nussberger, R. Sabat, T. Pfister, S. Ignatenko, H. D. Volk, H. Stocker, P. Müller, G. T. Jennings, et al. 2008. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet 371: 821-827.
49. Jennings, G. T., and M. F. Bachmann. 2008. The coming of age of virus-like particle vaccines. Biol. Chem. 389: 521-536.
50. Bélichard, P., M. Landry, P. Faye, D. R. Bachvarov, J. Bouthillier, D. Pruneau, and F. Marceau. 2000. Inflammatory hyperalgesia induced by zymosan in the plantar tissue of the rat: effect of kinin receptor antagonists. Immunopharmacology 46: 139-147. (Pubitemid 30019255)
51. Ugolini, G., S. Marinelli, S. Covaceuszach, A. Cattaneo, and F. Pavone. 2007. The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain. Proc. Natl. Acad. Sci. USA 104: 2985-2990.
52. Halvorson, K. G., K. Kubota, M. A. Sevcik, T. H. Lindsay, J. E. Sotillo, J. R. Ghilardi, T. J. Rosol, L. Boustany, D. L. Shelton, and P. W. Mantyh. 2005. A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res. 65: 9426-9435.
53. Dicou, E., D. Hurez, and V. Nerrière. 1993. Natural autoantibodies against the nerve growth factor in autoimmune diseases. J. Neuroimmunol. 47: 159-167.
54. Dicou, E., C. Masson, W. Jabbour, and V. Nerriere. 1993. Increased frequency of NGF in sera of rheumatoid arthritis and systemic lupus erythematosus patients. Neuroreport 5: 321-324.
55. Dicou, E., and V. Nerrière. 1997. Evidence that natural autoantibodies against the nerve growth factor (NGF) may be potential carriers of NGF. J. Neuroimmunol. 75: 200-203. (Pubitemid 27170320)
56. Dicou, E., V. Nerrière, and V. Labropoulou. 1991. Naturally occurring antibodies against nerve growth factor in human and rabbit sera: comparison between control and herpes simplex virus-infected patients. J. Neuroimmunol. 34: 153-158.
57. Dicou, E., S. Perrot, C. J. Menkes, C. Masson, and V. Nerriere. 1996. Nerve growth factor (NGF) autoantibodies and NGF in the synovial fluid: implications in spondylarthropathies. Autoimmunity 24: 1-9. (Pubitemid 26379162)
58. Dicou, E., P. Vermersch, I. Penisson-Besnier, F. Dubas, and V. Nerrière. 1997. Anti-NGF autoantibodies and NGF in sera of Alzheimer patients and in normal subjects in relation to age. Autoimmunity 26: 189-194. (Pubitemid 28014486)